Beam Therapeutics Inc.: ARK Investment Management LLC amends Schedule 13G stake filing
Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.
ARK Investment Management LLC amended its Schedule 13G filing on Beam Therapeutics Inc., disclosing a change in its passive stake in the gene-editing company under SEC accession 0001104659-26-126822. The filing updates ARK's previously reported beneficial ownership position in Beam, though the amended document did not specify the exact share count or percentage change in the headline disclosure. The move matters because ARK's flagship innovation-focused funds are closely watched as a barometer of institutional appetite for speculative biotech names such as Beam, whose base-editing platform remains pre-commercial. Investors will watch for the full amended filing details to confirm whether ARK added to or trimmed its position, and for any subsequent 13F or 13G updates that clarify the direction of the stake.
Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.
Named in this story
ARK Investment Management LLC, Beam Therapeutics Inc.